Work

Comment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘

Year: 2013

Type: letter

Abstract: As pointed out in the excellent article by Miles et al (2013) , the identification of patients benefiting most from bevacizumab remains elusive. The activity of the gemcitabine and platinum combination in a variety of neoplasms is well described. In metastatic breast cancer, it has often been used as a standard regimen in patients with triple-negative disease, despite a lack of comparative phase 3 data, especially in anthracycline and taxane pre-treated individuals ( Perez, 2004 ; Heinemann et al, 2006 ; Sanchez-Escribano Morcuende et al, 2007 ; Maisano et al, 2011 ). The role of gemcitabine and carboplatin in this setting has been highlighted by its use in the control arm in randomised trials of PARP inhibitors ( Foulkes et al, 2010 ; Stebbing et al, 2010 ; O'Shaughnessy, 2012 ).

Source: British Journal of Cancer

DOI: 10.1038/bjc.2013.279